Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk
Status:
Not yet recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the
chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with
advanced fibrosis at high risk of developing HCC.